- Home
- SPR vs RYTM Comparison
SPR vs RYTM Comparison
Compare SPR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPR
- RYTM
- Stock Information
- Founded
- SPR 1927
- RYTM 2008
- Country
- SPR United States
- RYTM United States
- Employees
- SPR N/A
- RYTM N/A
- Industry
- SPR Military/Government/Technical
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- SPR Industrials
- RYTM Health Care
- Exchange
- SPR Nasdaq
- RYTM Nasdaq
- Market Cap
- SPR 4.3B
- RYTM 4.3B
- IPO Year
- SPR 2006
- RYTM 2017
- Fundamental
- Price
- SPR $38.22
- RYTM $63.62
- Analyst Decision
- SPR Hold
- RYTM Strong Buy
- Analyst Count
- SPR 11
- RYTM 12
- Target Price
- SPR $36.56
- RYTM $77.50
- AVG Volume (30 Days)
- SPR 1.3M
- RYTM 560.2K
- Earning Date
- SPR 08-04-2025
- RYTM 08-05-2025
- Dividend Yield
- SPR N/A
- RYTM N/A
- EPS Growth
- SPR N/A
- RYTM N/A
- EPS
- SPR N/A
- RYTM N/A
- Revenue
- SPR $6,135,600,000.00
- RYTM $136,863,000.00
- Revenue This Year
- SPR $23.93
- RYTM $37.56
- Revenue Next Year
- SPR $14.86
- RYTM $74.99
- P/E Ratio
- SPR N/A
- RYTM N/A
- Revenue Growth
- SPR N/A
- RYTM 48.88
- 52 Week Low
- SPR $27.00
- RYTM $40.46
- 52 Week High
- SPR $39.00
- RYTM $69.89
- Technical
- Relative Strength Index (RSI)
- SPR 52.86
- RYTM 46.09
- Support Level
- SPR $36.71
- RYTM $60.70
- Resistance Level
- SPR $37.53
- RYTM $64.00
- Average True Range (ATR)
- SPR 0.56
- RYTM 2.22
- MACD
- SPR -0.12
- RYTM -0.39
- Stochastic Oscillator
- SPR 28.60
- RYTM 8.11
About SPR Spirit Aerosystems Holdings Inc.
Spirit AeroSystems manufactures aerostructures, particularly fuselages, cockpits, wing sections, engine pylons, and nacelles for commercial and military aircraft. The company was spun out of Boeing in 2005 to become the largest independent supplier of aerostructures for commercial aircraft. Boeing and Airbus are the firm's primary customers—Boeing represented roughly 60% and Airbus roughly 20% of revenue in recent years. The company is highly exposed to Boeing's beleaguered 737 program, which accounts for nearly half the company's revenue. The company plans to be acquired by and reintegrated into Boeing in mid-2025.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.